[UPOINT phenotypic classification of a sample of female patients with bladder pain syndrome: Results of a national multicentric observational study.] / Clasificación fenotípica UPOINT de una muestra de mujeres con síndrome de dolor vesical: resultados de un estudio observacional multicéntrico nacional.

OBJECTIVES: To study the possibility of classifying patients with BPS by UPOINT phenotypes and their correlation with the results of different BPS diagnostic tools. MATERIAL AND METHODS: Epidemiological, observational, longitudinal and multicentric study performed according to clinical practice. A total of 319 women with BPS were included, 79 with new diagnosis and 240 in follow-up. Sociodemographic and clinical data were collected together with results of cystoscopy, biopsy and physical examination. Patients completed a 3-day Bladder Diary (3dBD) and Patient Reported Outcomes (PROs). All the patients were classified according to the 6 UPOINT domains and their distribution was described according to the clinical history, diagnostic tests, urinary symptoms and PROs' scores. RESULTS: 92.8% of the patients had affectation in more than one phenotype, however, there were no remarkable differences in the clinical and sociodemographic variables according to the number of affected domains. The percentage of patients with 3C classification was higher in the urinary (8.2%), organ-specific (9.0%) and neurological (10.9%) phenotypes. Around 90% had high voiding frequency, regardless of the phenotype. The improvement reported by the PROs was superior in the neurological and tenderness phenotypes. The worst scores were associated with a greater number of affected domains. CONCLUSIONS: The present study is the first one carried out in Spain on a phenotypic classification of women with BPS, with data from routine clinical practice. The results point out that patients with several domains affected present more affectation on the BPS, worse HRQo Land higher anxiety.

OBJETIVOS: Estudiar la posibilidad de clasificar a las pacientes con SDV por los fenotipos UPOINT y su correlación con los resultados de otras herramientas diagnósticas para SDV. MATERIAL Y MÉTODOS: Estudio epidemiológico, observacional, longitudinal y multicéntrico realizado según la práctica clínica habitual. Se incluyeron 319 mujeres con SDV, 79 de nuevo diagnóstico y 240 en seguimiento. Se recogieron datos sociodemográficos y clínicos y resultados de la cistoscopia, biopsia y exploración física. Las pacientes cumplimentaron un diario miccional de 3 días y los Patient Reported Outcomes (PROs). Todas las pacientes fueron clasificadas según los 6 dominios UPOINT y se describió su distribución según la historia clínica, pruebas diagnósticas, síntomas urinarios y las puntuaciones de los PROs. RESULTADOS: El 92,8% de las pacientes tenían afectación en más de un fenotipo, sin embargo, no hubo diferencias destacables en las variables clínicas y sociodemográficas según el número de dominios afectados. El porcentaje de pacientes con clasificación 3C fue mayor en los fenotipos urológico (8,2%), órgano-específico (9,0%) y neurológico (10,9%). Alrededor del 90% presentaron frecuencia miccional elevada, independientemente del fenotipo. La mejoría reportada por los PROs fue superior en los fenotipos neurológico y tenderness. Las peores puntuaciones se asociaron a un mayor número de dominios afectados. CONCLUSIONES: El presente estudio es el primero realizado en España sobre una clasificación fenotípica de mujeres con SDV, basándose en datos de práctica clínica habitual. Los resultados obtenidos señalan una tendencia a que pacientes con afectación de varios dominios fenotípicos presentan mayor afectación por el SDV, peor CVRS y mayor ansiedad.

Clasificación fenotípica upoint de una muestra de mujeres con síndrome de dolor vesical: resultados de un estudio observacional multicéntrico nacional / Upoint phenotypic classification of a sample of women with bladder pain syndrome: results of a national multicenter observational study

Objetivos: Estudiar la posibilidad declasificar a las pacientes con SDV por los fenotiposUPOINT y su correlación con los resultados de otrasherramientas diagnósticas para SDV.Material y métodos: Estudio epidemiológico, observacional, longitudinal y multicéntrico realizado segúnla práctica clínica habitual. Se incluyeron 319 mujerescon SDV, 79 de nuevo diagnóstico y 240 en seguimiento. Se recogieron datos sociodemográficos y clínicosy resultados de la cistoscopia, biopsia y exploraciónfísica. Las pacientes cumplimentaron un diario miccional de 3 días y los Patient Reported Outcomes (PROs).Todas las pacientes fueron clasificadas según los 6 dominios UPOINT y se describió su distribución según lahistoria clínica, pruebas diagnósticas, síntomas urinariosy las puntuaciones de los PROs. Resultados: El 92,8% de las pacientes tenían afectación en más de un fenotipo, sin embargo, no hubodiferencias destacables en las variables clínicas y sociodemográficas según el número de dominios afectados.El porcentaje de pacientes con clasificación 3C fue mayor en los fenotipos urológico (8,2%), órgano-específico(9,0%) y neurológico (10,9%). Alrededor del 90% presentaron frecuencia miccional elevada, independiente-mente del fenotipo. La mejoría reportada por los PROsfue superior en los fenotipos neurológico y tenderness.Las peores puntuaciones se asociaron a un mayor número de dominios afectados.Conclusiones: El presente estudio es el primerorealizado en España sobre una clasificación fenotípicade mujeres con SDV, basándose en datos de prácticaclínica habitual. Los resultados obtenidos señalan unatendencia a que pacientes con afectación de variosdominios fenotípicos presentan mayor afectación por elSDV, peor CVRS y mayor ansiedad.(AU)

Objetives: To study the possibility ofclassifying patients with BPS by UPOINT phenotypesand their correlation with the results of different BPS diagnostic tools.Materials and methods: Epidemiological, observational, longitudinal and multicentric study performed according to clinical practice. A total of 319 women withBPS were included, 79 with new diagnosis and 240in follow-up. Sociodemographic and clinical data werecollected together with results of cystoscopy, biopsyand physical examination. Patients completed a 3-dayBladder Diary (3dBD) and Patient Reported Outcomes(PROs). All the patients were classified according to the6 UPOINT domains and their distribution was describedaccording to the clinical history, diagnostic tests, urinarysymptoms and PROs’ scores.Results: 92.8% of the patients had affectation in morethan one phenotype, however, there were no remarkable differences in the clinical and sociodemographicvariables according to the number of affected domains.The percentage of patients with 3C classification washigher in the urinary (8.2%), organspecific (9.0%) andneurological (10.9%) phenotypes. Around 90% hadhigh voiding frequency, regardless of the phenotype.The improvement reported by the PROs was superior inthe neurological and tenderness phenotypes. The worstscores were associated with a greater number of affected domains. Conclusions: The present study is the first one carried out in Spain on a phenotypic classification of women with BPS, with data from routine clinical practice. Theresults point out that patients with several domains affected present more affectation on the BPS, worse HRQoLand higher anxiety.(AU)

Laparoscopic Abdominopexy: Surgery for Vaginal Prolapse.

OBJECTIVES: We present a new surgery based on the round ligament anatomy that is called laparoscopic abdominopexy, which uses a synthetic mesh without fixation at any pelvic point. The aim of this study is to provide a step-by-step description of the laparoscopic abdominopexy technique and present the first anatomical and functional results of the procedure. METHODS: This prospective cohort study included patients with apical and anterior vaginal prolapse who were subjected to laparoscopic abdominopexy. Before and after surgery, the Pelvic Organ Prolapse Quantification (POP-Q) scale, Overactive Bladder Questionnaire-Short Form (OABq-SF), and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) were used to evaluate the vaginal prolapse stage, storage, and sexual symptoms, respectively. The surgical technique is described step by step. RESULTS: Twenty patients were included with follow-up times between 6 and 25 months. The mean surgical time was 78.4 minutes. A statistically significant improvement was observed in the Aa (P ≤ 10-5), Ba (P ≤ 10-5), C (P = 5 × 10-5), D (P = .002) and tvl (P = .02) POP-Q points and in OABq-SF (22.2%; P = .02). Successful surgery was observed in 100% of patients for the apical compartment and 90% of patients for the anterior compartment. CONCLUSION: Laparoscopic abdominopexy is a quick, safe, and reproducible surgical technique with beneficial anatomical and functional results that preserve the pelvic floor anatomy.

[Renal cell carcinoma metastases in rare anatomical locations: pituitary, thyroid and mammary glands. of our experience and report of three cases.] / Metástasis de carcinoma de células renales en localizaciones poco frecuentes: hipófisis, tiroides y mama. Revisión de nuestra experiencia y presentación de tres casos clínicos.

OBJECTIVE: Metastatic Renal Cell Carcinoma(RCC) may develop in different anatomical locationsand after a strict follow up within normal limits. We assessthe importance of close follow up in patients with historyof RCC through 3 clinical cases with unusual locations ofmetastatic RCC. METHODS: We present 3 cases of metastatic involvementof pituitary, thyroid and mammary glands. We retrospectivelyreview our data base on metastatic RCC with 76patients. DISCUSSION: There is not agreement about the time offollow up and image methods requested after surgery ofRCC. The reason is the development of late onset and atypicalplacement metastases. CONCLUSION: Metastatic disease of renal neoplasmscan occur at any time and at any location. It is importantto keep suspicion of metastatic renal disease in patients inthis background, even in those with good progress andregardless of the years that have passed since the initialdiagnosis.

OBJETIVO: El Carcinoma de Células Renales (CCR) metastásico puede presentarse en localizaciones anatómicas muy variables y tras varios años de seguimiento. En éste artículo resaltamos la importancia del seguimiento de pacientes con antecedente de CCR. MATERIAL Y MÉTODOS: A partir de la revisión de 76 casos de CCR metastásico que recibieron tratamiento sistémico, se presentan tres casos clínicos con afectación de glándulas hipófisis, tiroides y mama.DISCUSIÓN: Existe debate acerca del tiempo de seguimientotras una cirugía por CCR y los métodos de imagen de control por la posibilidad de aparición de metástasis tardías y en lugares atípicos.CONCLUSIÓN: Es importante mantener la sospecha de enfermedad renal metastásica en pacientes con antecedente de CCR, incluso en aquellos con buena evolución y sin tener en cuenta el tiempo transcurrido desde el diagnóstico inicial.

Metástasis de carcinoma de células renales en localizaciones poco frecuentes: hipófisis, tiroides y mama. Revisión de nuestra experiencia y presentación de tres casos clínicos / No disponible

Objetivo: El Carcinoma de Células Renales (CCR) metastásico puede presentarse en localizaciones anatómicas muy variables y tras varios años de seguimiento. En éste artículo resaltamos la importancia del seguimiento de pacientes con antecedente de CCR. Material y métodos: A partir de la revisión de 76 casos de CCR metastásico que recibieron tratamiento sistémico, se presentan tres casos clínicos con afectación de glándulas hipófisis, tiroides y mama. Discusión: Existe debate acerca del tiempo de seguimiento tras una cirugía por CCR y los métodos de imagen de control por la posibilidad de aparición de metástasis tardías y en lugares atípicos. Conclusión: Es importante mantener la sospecha de enfermedad renal metastásica en pacientes con antecedente de CCR, incluso en aquellos con buena evolución y sin tener en cuenta el tiempo transcurrido desde el diagnóstico inicial

Objective: Metastatic Renal Cell Carcinoma (RCC) may develop in different anatomical locations and after a strict follow up within normal limits. We assess the importance of close follow up in patients with history of RCC through 3 clinical cases with unusual locations of metastatic RCC. Methods: We present 3 cases of metastatic involvement of pituitary, thyroid and mammary glands. We retrospectively review our data base on metastatic RCC with 76 patients. DIscussion: There is not agreement about the time of follow up and image methods requested after surgery of RCC. The reason is the development of late onset and atypical placement metastases. Conclusion: Metastatic disease of renal neoplasms can occur at any time and at any location. It is important to keep suspicion of metastatic renal disease in patients in this background, even in those with good progress and regardless of the years that have passed since the initial diagnosis

[Laparoscopic ureteral reimplantation.] / Reimplante ureteral laparoscópico.

Although the laparoscopic ureteral reimplantation (LUR) has a history of over 20 years, its presence in the literature is relatively sparse, almost always in the form of small case series with low statistical power, which has prevented consistent results. It has proven to be a safe and effective technique, improving the safety profile and perioperative complications compared to open ureteral reimplantation (OUR). The few long-term results suggest a similar success rate between the open and laparoscopic approaches. Although we do not found in the literature a strong evidence of the benefits of anti-reflux reimplantation techniques in adults, most of the published series include these procedures. Ureteral reimplantation is considered the treatment of choice in ureteral injuries below the iliac vessels. This is its main indication now. Intraoperative recognition of the injury and immediate LUR avoid other complications, but most of ureteral injuries are diagnosed in the early postoperative period. Although the classical recommendations advise urinary diversion and delayed treatment, the immediate approach is feasible, and indeed seems to improve results in complications, stay and long-term renal function. In situations of postoperative peritonitis secondary to a ureteral fistula, immediate LUR offers specific advantages, at least theoretically, for the protective effect of pneumoperitoneum in abdominal sepsis.

Reimplante ureteral laparoscópico / Laparoscopic ureteral reimplantation

Aunque el reimplante ureteral laparoscópico (RUL) tiene una trayectoria de más de 20 años, su presencia en la literatura es relativamente escasa, casi siempre en forma de pequeñas series de casos con poca potencia estadística, lo que ha impedido obtener resultados consistentes. Ha demostrado ser una técnica segura y efectiva, mejorando el perfil de seguridad y complicaciones perioperatorias con respecto al reimplante ureteral abierto (RUA). Los escasos resultados a largo plazo sugieren una tasa de éxito similar entre los abordajes abierto y laparoscópico. Aunque no se han encontrado en la literatura evidencias firmes de las ventajas de las técnicas anti-reflujo en adultos, la mayor parte de las series publicadas incluyen estas técnicas. El reimplante ureteral se considera el tratamiento de elección en las lesiones ureterales por debajo del cruce iliaco. Ésta es su principal indicación actualmente. El reconocimiento intraoperatorio de la lesión y el RUL inmediato evitan otras complicaciones, pero la mayoría de las lesiones ureterales se diagnostican en el postoperatorio temprano. Aunque las recomendaciones clásicas aconsejan la derivación urinaria y tratamiento diferido, el abordaje inmediato es factible, y de hecho parece mejorar los resultados en complicaciones, estancia y función renal a largo plazo. En las situaciones postoperatorias de peritonitis secundarias a una fístula ureteral, el RUL inmediato ofrece ventajas específicas, al menos teóricamente, por el efecto protector del neumoperitoneo en las sepsis de origen abdominal

Although the laparoscopic ureteral reimplantation (LUR) has a history of over 20 years, its presence in the literature is relatively sparse, almost always in the form of small case series with low statistical power, which has prevented consistent results. It has proven to be a safe and effective technique, improving the safety profile and perioperative complications compared to open ureteral reimplantation (OUR). The few long-term results suggest a similar success rate between the open and laparoscopic approaches. Although we do not found in the literature a strong evidence of the benefits of anti-reflux reimplantation techniques in adults, most of the published series include these procedures. Ureteral reimplantation is considered the treatment of choice in ureteral injuries below the iliac vessels. This is its main indication now. Intraoperative recognition of the injury and immediate LUR avoid other complications, but most of ureteral injuries are diagnosed in the early postoperative period. Although the classical recommendations advise urinary diversion and delayed treatment, the immediate approach is feasible, and indeed seems to improve results in complications, stay and long-term renal function. In situations of postoperative peritonitis secondary to a ureteral fistula, immediate LUR offers specific advantages, at least theoretically, for the protective effect of pneumoperitoneum in abdominal sepsis

Angiomiolipoma renal en un paciente con esclerosis tuberosa. Presentación de un caso clínico / Renal angiomyolipoma in a patient with tuberous sclerosis. Case report

OBJETIVO: Resaltar la importancia del manejo y seguimiento estrecho de pacientes con esclerosis tuberosa que asocian angiomiolipomas renales. MÉTODOS: Presentación de un caso clínico. RESULTADOS: Se trata de un paciente varón de 55 años de edad diagnosticado de esclerosis tuberosa en la infancia con posterior hallazgo de masas renales bilaterales y de gran tamaño en estudio de imagen, con compromiso importante de la función renal. El paciente no tuvo un seguimiento adecuado ni recibió tratamiento alguno. Al momento se encuentra en estadio terminal de su enfermedad renal. CONCLUSIÓN: Los pacientes que asocian angiomiolipomas renales y esclerosis tuberosa, presentan características particulares con mayor riesgo de complicaciones por lo que requieren un seguimiento estricto y un manejo específico

OBJECTIVE: To assess the importance of management and close follow-up of patients with tuberous sclerosis that associate renal angiomyolipomas. METHODS: To report a case. RESULTS: A 55 years old men with tuberous sclerosis diagnosed in childhood and later finding of bilateral giant renal masses in imaging studies, with significant compromise of renal function. The patient did not have a proper follow up and did not receive any treatment. At the moment he has end stage kidney disease. CONCLUSION: Patients that associate renal angiomyolipoma and tuberous sclerosis, have specific characteristics with a higher risk of complications requiring strict follow-up and specific treatment

[Renal angiomyolipoma in a patient with tuberous sclerosis. Case report.] / Angiomiolipoma renal en un paciente con esclerosis tuberosa. Presentación de un caso clínico.

OBJECTIVE: To assess the importance of management and close follow-up of patients with tuberous sclerosis that associate renal angiomyolipomas. METHODS: To report a case. RESULTS: A 55 years old men with tuberous sclerosis diagnosed in childhood and later finding of bilateral giant renal masses in imaging studies, with significant compromise of renal function. The patient did not have a proper follow up and did not receive any treatment. At the moment he has end stage kidney disease. CONCLUSION: Patients that associate renal angiomyolipoma and tuberous sclerosis, have specific characteristics with a higher risk of complications requiring strict follow-up and specific treatment.

Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience.

OBJECTIVES: To study the validity of Matrix Metalloproteinase 9 as a complementary marker to PSA for the diagnosis and prognosis of Prostate Cancer. METHODS: Prospective study structured as a hospital-based cohort of 100 consecutive patients undergoing prostate biopsy. Serum determination of MMP-9 was carried out by means of inmunoassay. Statistical analysis was performed using the Stata/SE 8.2 software. RESULTS: 32 patients were diagnosed with prostate cancer and 52% had a Gleason score equal to or greater than 7. The values of serum MMP-9 varied between 225.7 and 1932.3 ng/ml, without significant differences among patients with benign, malignant and uncertain histology (p=0.429). The differences approached statistical significance in the subgroup of patients with PSA at 4-10 ng/ml (p=0.058), and significant differences were observed in the subgroup with free PSA to total PSA coefficient of less than 15% (p=0.037). No relationship between the Gleason score and the level of MMP-9 was shown (p=0.739). The levels of PSA and MMP-9 were shown to be independent (Pearson coefficient of correlation -0.1). CONCLUSIONS: It was not possible to show the efficacy of MMP-9 in predicting the result of the biopsy. In the group of patients with slightly increased levels of PSA (between 4 and 10 ng/ml) all the descriptive variables were higher in the group with malignant histology, though they did not reach statistical significance, they did reach significance when the coefficient of free PSA over total PSA was less than 15%, but this finding is not relevant clinically, as these patients already have a clear indication for biopsy. Neither was the relationship with the prognosis shown as there are no differences of MMP-9 expression at varying Gleason scores.

Matrix metalloproteinase- 9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience.

UNLABELLED: Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer. OBJECTIVES: To establish the presence of the MMP-9's gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score. METHODS: Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique. RESULTS: No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms. CONCLUSION: The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancer.

Expresión de metaloproteasa de matriz 9 en el cáncer de próstata. Experiencia preliminar / Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience

OBJETIVO: Estudiar la validez de la metaloproteasa 9 (MMP-9) como marcador complementario al PSA en el diagnóstico y el pronóstico del carcinoma de próstata.MÉTODO: Estudio prospectivo estructurado como cohorte de base hospitalaria. Fueron incluidos 100 pacientes consecutivos a los que se iba a practicar una biopsia prostática. La determinación sérica de MMP-9 se realizó mediante inmunoensayo, y el análisis estadístico con el programa informático stata/SE 8.2.RESULTADOS: 32 pacientes fueron diagnosticados de carcinoma prostático y el 52% de ellos con grado Gleason mayor o igual a 7. Los valores de MMP-9 sérica oscilaron entre 225,7 y 1932,3 nanogramos por mililitro, sin encontrar diferencias estadísticamente significativas entre los pacientes con histología benigna, maligna e incierta (p=0,429). Las diferencias se acercaron a la significación estadística en el subgrupo de pacientes con PSA 4-10 ng/ml (p=0,058) y en el subgrupo PSA libre/total menor de 15% se observaron diferencias significativas (p=0,037). No se encontró relación entre el grado Gleason y el nivel de MMP-9 (p=0,739). Los niveles de PSA y MMP-9 demostraron ser independientes (Coeficiente de correlación de Pearson -0,1).CONCLUSIONES: No fue posible demostrar la eficacia de la MMP-9 para predecir el resultado de la biopsia. En el grupo de pacientes con elevaciones discretas del PSA (entre 4 y 10 ng/ml) todas las variables descriptivas fueron superiores en el grupo con histología maligna, sin alcanzar la significación estadística. Sí se alcanzó la significación cuando el cociente de PSA libre entre PSA total fue menor del 15%, pero este hallazgo no tiene relevancia en la práctica clínica, pues estos pacientes ya tienen indicación clara de biopsia. Tampoco se demuestra relación con el pronóstico al no existir diferencias de expresión de MMP-9 entre diferentes grados Gleason(AU)

OBJECTIVES: To study the validity of Matrix Metalloproteinase 9 as a complementary marker to PSA for the diagnosis and prognosis of Prostate Cancer.METHODS: Prospective study structured as a hospital-based cohort of 100 consecutive patients undergoing prostate biopsy. Serum determination of MMP-9 was carried out by means of inmunoassay . Statistical analysis was performed using the Stata/SE 8.2 software.RESULTS: 32 patients were diagnosed with prostate cancer and 52% had a Gleason score equal to or greater than 7. The values of serum MMP-9 varied between 225.7 and 1932.3 ng/ml, without significant differences among patients with benign, malignant and uncertain histology (p=0.429). The differences approached statistical significance in the subgroup of patients with PSA at 4-10 ng/ml (p=0.058), and significant differences were observed in the subgroup with free PSA to total PSA coefficient of less than 15% (p=0.037). No relationship between the Gleason score and the level of MMP-9 was shown (p=0.739). The levels of PSA and MMP-9 were shown to be independent (Pearson coefficient of correlation -0.1).CONCLUSIONS: It was not possible to show the efficacy of MMP-9 in predicting the result of the biopsy. In the group of patients with slightly increased levels of PSA (between 4 and 10 ng/ml) all the descriptive variables were higher in the group with malignant histology, though they did not reach statistical significance, they did reach significance when the coefficient of free PSA over total PSA was less than 15%, but this finding is not relevant clinically, as these patients already have a clear indication for biopsy. Neither was the relationship with the prognosis shown as there are no differences of MMP-9 expression at varying Gleason scores(AU)

Polimorfismo de la metaloproteasa de matriz 9 (MMO-9) en el diagnostico del carcinoma prostático. Experiencia preliminar / Matrix metalloproteinase 9 polyphormisms in the diagnosis of prostate cancer. A preliminary experience

Los polimorfismos Q279R, P574R y -1562 C/T en el gen de la MMP-9 se han relacionado con el riesgo de padecer cáncer y con la agresividad tumoral de varios tipos de cánceres. Hasta ahora no existen estudios en la literatura que analicen la asociación de los polimorfismos Q279R, P574R y -1562 C/T de la MMP-9 con el cáncer prostático.OBJETIVOS: Determinar las diferencias de presencia de los polimorfismos en el gen de la MMP-9 (Q279R, P574R y -1562 C/T) en función del resultado de la biopsia prostática, de las cifras del PSA y el grado histológico Gleason.MÉTODOS: Se trata de una cohorte de base hospitalaria que incluye 100 pacientes con sospecha de carcinoma prostático, sometidos a biopsia prostática, a los que se determinaron los polimorfismos de la MMP-9 (Q279R, P574R y -1562 C/T) mediante la técnica de PCR-RFLP.RESULTADOS: No se encontraron diferencias estadísticamente significativas en la presencia de los polimorfismos Q279R, P574R y -1562 C/T de la MMP-9, en función del resultado de la biopsia prostática (p = 0,264, p = 0,406, p = 0,860, respectivamente), ni en función del grado Gleason (p = 0,373, p = 0,367, p = 0,476). Al comparar los distintos genotipos de los polimorfismos Q279R y P574R de la MMP-9 en función del resultado de la biopsia prostática, haciendo subgrupos según las cifras del PSA, tampoco se encontraron diferencias estadísticamente significativas (p = 0,332 y p = 0,393, respectivamente). Se encontraron diferencias estadísticamente significativas al comparar los distintos genotipos del polimorfismo -1562 C/T de la MMP-9, en pacientes con biopsia positiva para tumor maligno respecto a biopsia negativa para tumor maligno en el subgrupo de pacientes de PSA > 10 ng/ml (p = 0,049)...(AU)

Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer.OBJECTIVES: To establish the presence of the MMP-9´s gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score.METHODS: Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique.RESULTS: No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, , using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA > 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms.CONCLUSION: The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancer(AU)